Vertex Pharmaceuticals Inc

“Vertex owns one of the most durable moats in biopharma — a near-monopoly CF franchise with $12B revenue, 54% gross margins, $7B+ net cash, and a decade of reinvestment runway into pain, renal, and gene therapy. The CF business is fully priced at 20x forward earnings, and meaningful stock upside from current levels requires suzetrigine or povetacicept to reach commercial scale. The probability of permanent capital impairment is low; the probability of above-average returns from today's price is moderate at best. Track for a 10-15% pullback toward $365-390 to widen the margin of safety.”